Posted by Michael Wonder on 13 Nov 2024
Alectinib hydrochloride for the adjuvant treatment of patients with ALK positive non-small-cell lung cancer
13 November 2024 - NICE has published final evidence-based recommendations on the use of alectinib hydrochloride for the adjuvant treatment of adults with ALK positive non-small-cell lung cancer.
Alectinib hydrochloride is recommended as an option for the adjuvant treatment of adults with stage 1B (tumours 4 cm or larger) to 3A ALK positive non-small-cell lung cancer after complete tumour resection.
It is only recommended if Roche provides it according to the commercial arrangement.
